Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 75,000 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the transaction, the chief executive officer owned 1,021,180 shares of the company’s stock, valued at approximately $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded down $0.08 during midday trading on Thursday, hitting $14.27. The company had a trading volume of 10,838,894 shares, compared to its average volume of 11,160,116. The firm has a fifty day simple moving average of $12.03 and a two-hundred day simple moving average of $9.18. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $14.38. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The stock has a market cap of $4.40 billion, a price-to-earnings ratio of -356.66 and a beta of 0.42.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The firm had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. During the same period in the previous year, the company posted $0.10 earnings per share. The company’s quarterly revenue was up 19.5% compared to the same quarter last year. Equities analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in FOLD. Osaic Holdings Inc. raised its stake in shares of Amicus Therapeutics by 450.1% in the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Amicus Therapeutics by 167.1% during the 4th quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,243 shares in the last quarter. Strs Ohio bought a new position in Amicus Therapeutics in the 1st quarter valued at $30,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Amicus Therapeutics during the third quarter worth $31,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group restated a “hold” rating and issued a $14.50 price objective (down previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday. Leerink Partners lowered Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $17.00 to $14.50 in a research note on Monday, December 29th. TD Cowen downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price for the company. in a research report on Monday, December 22nd. Needham & Company LLC lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $15.55.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.